Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats

Frontiers in Physiology

Volumn 4 JUL, Issue , 2013, Pages

  Schierwagen, Robert ^a   Leeming, Diana J ^b   Klein, Sabine ^a   Granzow, Michaela ^a   Nielsen, Mette J ^b,c   Sauerbruch, Tilman ^a   Krag, Aleksander ^c   Karsdal, Morten A ^b   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b NORDIC BIOSCIENCE A S   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antifibrotic; ECM (extracellular matrix); Fibrosis; Markers; remodeling; Statins

Indexed keywords

ATORVASTATIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 6; COLLAGENASE 3; EPITOPE; GELATINASE A; GELATINASE B; HYDROXYPROLINE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; EARLY INTERVENTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WILD TYPE; ZYMOGRAPHY;

EID: 84884541673     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00195     Document Type: Article

References (30)

1. Arena, U., Vizzutti, F., Corti, G., Ambu, S., Stasi, C., Bresci, S., et al. (2008). Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 47, 380-384. doi: 10.1002/hep.22007
2. Barascuk, N., Veidal, S. S., Larsen, L., Larsen, D. V., Larsen, M. R., Wang, J., et al. (2010). A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin. Biochem. 43, 899-904. doi: 10.1016/j.clinbiochem.2010.03.012
3. Bataller, R., and Brenner, D. A. (2005). Liver fibrosis. J. Clin. Invest. 115, 209-218.
4. Bedossa, P., Dargere, D., and Paradis, V. (2003). Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38, 1449-1457.
5. Brundtland, G. H. (2002). From the World Health Organization. Reducing risks to health, promoting healthy life. JAMA 288, 1974. doi: 10.1001/jama.288.16.1974
6. Coco, B., Olivieri, F., Maina, A. M., Ciccorossi, P., Sacco, R., Colombatto, P., et al. (2007). Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J. Viral Hepat. 14, 360-369. doi: 10.1111/j.1365-2893.2006.00811.x
7. Friedman, S. L. (Ed.). (2001). "The hepatic stellate cell," in Semin Liver Dis. (New York, NY: Thieme), 307-452.
8. Friedman, S. L. (2003). Liver fibrosis-from bench to bedside. J. Hepatol. 38(Suppl. 1), S38-S53. doi: 10.1016/S0168-8278(02)00429-4
9. Friedman, S. L. (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669. doi: 10.1053/j.gastro.2008.03.003
10. Gressner, A. M., and Weiskirchen, R. (2006). Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J. Cell. Mol. Med. 10, 76-99. doi: 10.1111/j.1582-4934.2006.tb00292.x
11. Karsdal, M. A., Henriksen, K., Leeming, D. J., Mitchell, P., Duffin, K., Barascuk, N., et al. (2009). Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 14, 181-202. doi: 10.1080/13547500902777608
12. Karsdal, M. A., Henriksen, K., Leeming, D. J., Woodworth, T., Vassiliadis, E., and Bay-Jensen, A. C. (2010). Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin. Biochem. 43, 793-804. doi: 10.1016/j.clinbiochem.2010.03.015
13. Karsdal, M. A., Nielsen, M. J., Sand, J. M., Henriksen, K., Genovese, F., Bay-Jensen, A. C., et al. (2012). Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev. Technol. 11, 70-92. doi: 10.1089/adt.2012.474
14. Klein, S., Klosel, J., Schierwagen, R., Korner, C., Granzow, M., Huss, S., et al. (2012). Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab. Invest. 92, 1440-1450. doi: 10.1038/labinvest.2012.106
15. Koch, A., Horn, A., Duckers, H., Yagmur, E., Sanson, E., Bruensing, J., et al. (2011). Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICU. Crit. Care 15, R266.
16. Leeming, D., He, Y., Veidal, S., Nguyen, Q., Larsen, D., Koizumi, M., et al. (2011). A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16, 616-628. doi: 10.3109/1354750X.2011.620628
17. Leeming, D. J., Byrjalsen, I., Jiménez., Christiansen, C., and Karsdal, M. A. (2013). Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis-a serological evaluation. Liver Int. 33, 439-447. doi: 10.1111/liv.12044
18. Leeming, D. J., Nielsen, M. J., Dai, Y., Veidal, S. S., Vassiliadis, E., Zhang, C., et al. (2012). An Enzyme-linked Immunosorbent Serum Assay (ELISA) specific for the 7S domain of Collagen Type IV (PIVNP 7S) -a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol. Res. 42, 482-493. doi: 10.1111/j.1872-034X.2011.00946.x
19. Millonig, G., Friedrich, S., Adolf, S., Fonouni, H., Golriz, M., Mehrabi, A., et al. (2010). Liver stiffness is directly influenced by central venous pressure. J. Hepatol. 52, 206-210.
20. Millonig, G., Reimann, F. M., Friedrich, S., Fonouni, H., Mehrabi, A., Buchler, M. W., et al. (2008). Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 48, 1718-1723. doi: 10.1002/hep.22577
21. Nielsen, M. J., Nedergaard, A. F., Sun, S., Veidal, S. S., larsen, L., Zheng, Q., et al. (2013). The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am. J. Trans. Res. 5, 303-315.
22. Parola, M., Marra, F., and Pinzani, M. (2008). Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol. Aspects 29, 58-66. doi: 10.1016/j.mam.2007.09.002
23. Pinzani, M. (2002). PDGF and signal transduction in hepatic stellate cells. Front. Biosci. 7, d1720-d1726.
24. Trabut, J. B., Thepot, V., Nalpas, B., Lavielle, B., Cosconea, S., Corouge, M., et al. (2012). Rapid decline of liver stiffness following alcohol withdrawal in heavy drinkers. Alcohol. Clin. Exp. Res. 36, 1407-1411. doi: 10.1111/j.1530-0277.2012.01737.x
25. Trebicka, J., Hennenberg, M., Laleman, W., Shelest, N., Biecker, E., Schepke, M., et al. (2007). Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46, 242-253. doi: 10.1002/hep.21673
26. Trebicka, J., Hennenberg, M., Odenthal, M., Shir, K., Klein, S., Granzow, M., et al. (2010). Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Hepatol. 53, 702-712. doi: 10.1016/j.jhep.2010.04.025
27. Trebicka, J., Leifeld, L., Hennenberg, M., Biecker, E., Eckhardt, A., Fischer, N., et al. (2008). Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47, 1264-1276. doi: 10.1002/hep.22170
28. Vassiliadis, E., Larsen, D. V., Clausen, R. E., Veidal, S. S., Barascuk, N., Larsen, L., et al. (2011). Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomark Insights 6, 49-58. doi: 10.4137/BMI.S6347
29. Veidal, S. S., Karsdal, M. A., Nawrocki, A., Larsen, M. R., Dai, Y., Zheng, Q., et al. (2011a). Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 4:22. doi: 10.1186/1755-1536-4-22
30. Veidal, S. S., Karsdal, M. A., Vassiliadis, E., Nawrocki, A., Larsen, M. R., Nguyen, Q. H., et al. (2011b). MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS ONE 6:e24753. doi: 10.1371/journal.pone.0024753